|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
RT-qPCR confirmed the microarray findings and was used to investigate MT3 mRNA gene expression in tumor samples of a series of 52 different pituitary adenoma subtypes comprising 10 corticotropin (ACTH)-producing, 18 growth hormone (GH)-producing, 8 prolactin (PRL)-producing, and 16 nonfunctional adenomas.
|
16601360 |
2005 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Bcl-2-associated athanogene (BAG1), an anti-apoptotic protein found at high levels in a number of human cancers, was significantly over-expressed in growth hormone-secreting and prolactin-secreting adenomas and NFPAs.
|
15994756 |
2005 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Female patients were slightly younger and, in all adenoma categories, less often had invasive tumors: PRL (15%/30%), ACTH (17%/44%), LH/FSH (8%/27%) and null cell adenomas (0%/27%).
|
15803804 |
2005 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
BIM-23244 reduced PRL secretion only in adenomas expressing sst2, sst5 and DR2. sst5 and DR2 expression correlated directly with BIM23206 inhibitory effects on PRL secretion.
|
16216913 |
2005 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Second, compared with OCT, SOM230 is more potent in inhibiting PRL release by mixed GH/PRL-secreting adenoma and prolactinoma cells.
|
15070915 |
2004 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No specific TPIT immunostaining was detectable in all prolactin (PRL)-, GH-, or gonadotropin-secreting adenomas.
|
12843142 |
2003 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The folate receptor (FRalpha) was significantly overexpressed in clinically nonfunctional (NF) adenomas but not in functional adenomas (adrenocorticorticotropic hormone, growth hormone, and prolactin).
|
12874029 |
2003 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Seventeen of 32 (53.1%) tumours showed somatic-activating mutations of GNAS1: 16 (53.3%) of 30 GH-secreting adenomas and one of two GH and PRL-secreting adenomas.
|
12641630 |
2003 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We investigated the effects of SRIF and a SSTR1 selective agonist, BIM-23926, on GH and prolactin (PRL) secretion and cell viability in primary cultures deriving from 15 GH- and PRL-secreting adenomas expressing SSTR1.
|
12788890 |
2003 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
It should be noted that the PRL response to TRH in prolactinoma or an abnormal response of gonadotropin and/or its subunits to TRH in gonadotroph cell adenomas is considered to be due to a mechanism other than direct TRH action in adenoma cells.
|
14599121 |
2003 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Double staining techniques revealed the co-expression of p21/WAF1/GH or p21/WAF1/PRL in functioning adenomas.
|
12111504 |
2002 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
CTD_human |
SUNCT syndrome in two patients with prolactinomas and bromocriptine-induced attacks.
|
12058109 |
2002 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
A 59-year-old man with a giant adenoma in his pituitary had elevated serum prolactin (PRL) and insulin-like growth factor (IGF)-I levels, despite normal levels of basal GH.
|
12008749 |
2002 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In the pituitary gland, activating mutations of the GNAS1 (Gsalpha) gene at Gln227 have been identified in adrenocorticotrophin secreting, growth hormone secreting, and prolactin secreting adenomas.
|
11836449 |
2002 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In 35% of the cases the adenoma was nonfunctional, while in the others it was associated with PRL, GH and/or ACTH endocrine hypersecretion syndrome.
|
12011941 |
2002 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition,1 of 2 ACTH tumors but no GH (n = 4) or PRL (n = 1) adenoma examined were hypermethylated.
|
11740049 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Forty-four GH-secreting adenomas, 7 prolactin (PRL)-secreting adenomas and 32 clinically non-functioning adenomas were examined for the presence of point mutations in codon 201 and 227 of the Gs alpha gene using a nested PCR and direct sequencing of DNA extracted from fresh tissue or paraffin-embedded pituitary adenoma samples.
|
11182759 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Bromocriptine (BC) is a well known anti-neoplasic agent in human PRL secreting adenomas although its effect on PRL cells is far from clear.
|
11680511 |
2001 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
ISH detected signals for all pituitary hormones at a range of 30% for prolactin (PRL) to 85% for proopiomelanocortin (POMC). mRNA for beta-FSH was detected in 70% and beta-LH mRNA in 43% of adenomas.
|
11579683 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Prolactin-secreting adenomas (prolactinomas) are the most prevalent form of pituitary tumors in humans, and increased tumor growth under estrogenic influence in female patients is often of clinical concern.
|
11587556 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Folate receptor gene was significantly overexpressed in nonfunctioning adenomas but was significantly underexpressed in PRL and GH adenomas, compared with controls and to other tumors.
|
11443173 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Dopamine agonists inhibit hormone release and induce tumor shrinkage in most prolactin-secreting adenomas, whereas in other adenoma types such effects are sporadic.
|
11444429 |
2001 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Ptx1 was detected in 10/14 (71.4%) of growth hormone (GH)-secreting adenomas, 12/12 (100%) of prolactin (PRL)-secreting adenomas, 18/20 (90%) of adrenocorticotropic hormone (ACTH)-secreting adenomas, 6/7 (85.7%) of thyroid-stimulating hormone (TSH)-secreting adenomas, and 17/20 (85%) of clinically non-functioning adenomas, including 9/10 (90%) of gonadotropin-subunit-positive adenomas.
|
11048804 |
2000 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In cells cultured from the 10 mixed adenomas that secreted both GH and PRL, RT-PCR analysis revealed a consistent coexpression of SSTR5, SSTR2, and SSTR1 mRNA.
|
10690891 |
2000 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Six patients had prolactin-secreting adenomas, three had adrenocorticotropic hormone-secreting adenomas, one had a growth hormone -secreting adenoma, and three had non-secreting adenomas.
|
10984631 |
2000 |